Synapse - Find an Expert

115370 Results

Real-word effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Meeting Abstract

Rampal, R.; Marrone, M.; Morere, L.; Oladapo, A.; Suthar, P.; Sura, T.; Vasudevan, A.; Vredenburg, M.; Zeng, J.; Mascarenhas, J. O.
Blood (2024)

Fulltext@MSK | Save

Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma

Meeting Abstract

Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
Blood (2024)

Fulltext@MSK | Save

High WEE1 expression correlates with poor survival in multiple myeloma, independent of standard prognostic factors

Meeting Abstract

Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
Blood (2024)

Fulltext@MSK | Save

A phase 1/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis

Meeting Abstract

Mascarenhas, J. O.; Rampal, R.; El Chaer, F.; Gupta, V.; Shimoda, K.; Kiladjian, J. J.; Passamonti, F.; Bose, P.; Scandura, J. M.; Mesa, R.; more...
Blood (2024)

Fulltext@MSK | Save

River-52: A multicenter, open-label clinical trial of RVU120 in patients with relapsed or refractory high-risk myelodysplastic syndrome or acute myeloid leukemia

Meeting Abstract

Papayannidis, C.; Madry, K.; Centkowski, P.; Prejzner, W.; Butrym, A.; Chraniuk, D.; Saba, C.; Angelosanto, N.; Curley, R.; Nogai, H.; more...
Blood (2024)

Fulltext@MSK | Save

A phase 1, multicenter, open-label, dose-escalation study to evaluate safety, tolerability, pharmacokinetics, and clinical activity of orally administered LP-108 (lacutoclax) as monotherapy and in combination with azacitidine in subjects with relapsed or refractory myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML)

Meeting Abstract

Burgues, J. M. B.; Koenig, K.; Montesinos, P.; Bixby, D. L.; Burke, P. W.; Daver, N.; Anthony, S. P.; Tan, F. L.; Chen, Y.; Chen, Y.; more...
Blood (2024)

Fulltext@MSK | Save

Preliminary safety and efficacy of emavusertib (CA-4948) in combination with ibrutinib in relapsed/refractory primary central nervous system lymphoma patients with prior exposure to BTK inhibitor

Meeting Abstract

Nowakowski, G. S.; Dabrowska-Iwanicka, A. P.; Grommes, C.; Tun, H. W.; D'Angelo, C.; Burguera, A. D.; Levi, E.; Ramchandren, R.; Ferreri, A. J. M.; Choudhary, G. S.; more...
Blood (2024)

Fulltext@MSK | Save

Novel nilotinib tablet formulation: Pharmacokinetic characterization and effects of food

Meeting Abstract

Mauro, M. J.; Radich, J. P.; Jain, P.; Sequeira, D.; Douer, D.
Blood (2024)

Fulltext@MSK | Save

Real-world (RW) outcomes for brexucabtagene autoleucel (Brexu-Cel) treatment in patients (Pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) by high-risk features and prior treatments: Updated evidence from the CIBMTR® registry